Global Adalimumab Biosimilar Market Size By Type (Tablet, Oral Solution), By Application (Hospital Pharmacy, Retail Pharmacy), By Region, And Segment Forecasts, 2023 to 2032

The Global Adalimumab Biosimilar Market was valued at USD 4.9 billion in 2023 and is projected to reach USD 14.6 billion by 2031, growing at a CAGR of 14.4% during the forecast period of 2023–2031. This growth is primarily driven by the increasing prevalence of autoimmune diseases, rising demand for cost-effective biologics, and growing regulatory approvals for biosimilar versions of adalimumab. With the expiration of patents for branded biologics like Humira®, biosimilars have emerged as viable and affordable alternatives, significantly boosting their market penetration worldwide.

Drivers:

1. Increasing Incidence of Autoimmune Diseases:

The rising global prevalence of autoimmune conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease is a major driver. Adalimumab biosimilars offer effective therapeutic solutions at a lower cost compared to branded biologics, thereby encouraging broader adoption.

2. Cost-Effectiveness and Healthcare Savings:

Biosimilars provide comparable efficacy and safety to originator biologics at a significantly reduced price, resulting in substantial savings for both healthcare systems and patients.

3. Patent Expiries and Regulatory Approvals:

The expiry of Humira® patents has opened doors for multiple biosimilar entries. Favorable regulatory environments in regions like Europe and the U.S. are accelerating approvals and fostering competitive pricing.

Restraints:

1. Market Access and Reimbursement Barriers:

Despite regulatory approvals, access to biosimilars can be hindered by complex reimbursement frameworks and limited physician awareness in some regions.

2. Brand Loyalty to Originators:

Physician and patient loyalty to original biologics due to longstanding clinical data and trust can pose challenges for biosimilar uptake.

Opportunity:

1. Expansion in Emerging Markets:

Countries in Asia-Pacific, Latin America, and parts of the Middle East are investing in biosimilar adoption to enhance treatment accessibility. This creates lucrative growth opportunities for manufacturers.

2. Ongoing Clinical Development and Portfolio Diversification:

Several pipeline biosimilars for different indications and delivery systems are being developed, expanding the scope of adalimumab biosimilars across therapeutic areas.

Market by System Type Insights:

Based on product type, the conventional adalimumab biosimilars segment dominated the market in 2023. These include prefilled syringes and autoinjectors mirroring the reference product. The segment continues to grow due to high adoption among patients and healthcare providers, offering familiar modes of delivery and proven efficacy.

Market by End-Use Insights:

The hospital pharmacy segment accounted for the largest market share in 2023. Hospitals are the primary distribution channel for biosimilars due to centralized procurement and the ability to negotiate bulk pricing. Additionally, the retail pharmacy segment is expected to witness robust growth due to rising outpatient prescriptions and patient preference for home-based therapy.

Market by Regional Insights:

Europe led the global adalimumab biosimilar market in 2023, supported by early regulatory approvals, strong healthcare reimbursement systems, and favorable biosimilar policies. North America is projected to experience the fastest growth during the forecast period, driven by an increasing number of biosimilar launches and greater market acceptance following recent FDA approvals. Asia-Pacific also presents strong growth prospects due to expanding healthcare access and biosimilar-focused healthcare strategies.

Competitive Scenario:

Key players in the Global Adalimumab Biosimilar Market include Amgen Inc., Biocon Biologics, Boehringer Ingelheim, Samsung Bioepis, Mylan N.V., Sandoz (a Novartis Division), Pfizer Inc., Fresenius Kabi, Coherus BioSciences, and Celltrion Healthcare. These companies are actively pursuing product launches, collaborations, and market expansions to consolidate their presence.

Key developments include:

In 2023, Amgen expanded its Amjevita™ biosimilar into new geographies, strengthening its market leadership.

Biocon Biologics received FDA approval in 2023 for Hulio™, enabling entry into the U.S. market.

Pfizer announced in 2024 its strategic partnerships with payers and providers to improve biosimilar access and affordability in North America.

Scope of Work – Global Adalimumab Biosimilar Market

Key Market Developments:

2023: Samsung Bioepis and Biogen expanded the availability of Imraldi™ across additional European markets.

2024: Coherus BioSciences announced the launch of Yusimry™ with competitive pricing in the U.S.

2025: Fresenius Kabi received marketing authorization in Europe for its adalimumab biosimilar targeting multiple autoimmune conditions.

FAQs:

1) What is the current market size of the Global Adalimumab Biosimilar Market?

The market was valued at USD 4.9 billion in 2023.

2) What is the major growth driver of the Global Adalimumab Biosimilar Market?

The primary growth driver is the rising demand for cost-effective biologic alternatives for treating autoimmune diseases.

3) Which is the largest region during the forecast period in the Global Adalimumab Biosimilar Market?

Europe is currently the largest region, while North America is expected to grow at the fastest rate.

4) Which segment accounted for the largest market share in the Global Adalimumab Biosimilar Market?

The hospital pharmacy segment held the largest market share in 2023.

5) Who are the key market players in the Global Adalimumab Biosimilar Market?

Key players include Amgen, Biocon Biologics, Boehringer Ingelheim, Samsung Bioepis, Pfizer, and Sandoz.